While type 2 diabetes (T2D) is commonly seen in primary care, it is difficult to manage successfully over time. This series offers brief eNewsletters written by clinical experts that are designed to assist in the clinical management of patients with T2D.
Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors
Publish date: December 15, 2016
This third eNewsletter in the series, entitled, Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors , was written by Matthew L. Mintz, MD. It explores how the kidney helps to maintain glucose homeostasis and how dysfunctional glucose reabsorption by the sodium-glucose cotransporter-2 (SGLT-2) contributes to the pathophysiology of T2D. The effect of SGLT-2 inhibitors on glycemic control, body weight, blood pressure, and uric acid levels in patients with T2D are also discussed.
Recommended for You
Articles from The Journal of Family Practice
Quizzes from MD-IQ
Research Summaries from ClinicalEdge
How to protect your patient—and yourself—when prescribing opioids
Statins for primary prevention of CVD: To start or not to start?
What FPs need to know about naloxone kits
Need an edge with T2DM? The case for team-based care
CDC: 4 conception strategies for HIV-discordant couples
- Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment
- Using Multi-Condition Assessment to Optimize Management of Mental Health in Primary Care
- Effect of Non–Insulin-Based Glucose-Lowering Therapies on Cardiovascular Outcomes in Patients With Type 2 Diabetes
Hot Topics in Primary Care
- The Benefits and Risks of Oral Antiplatelet Therapy in Patients With Acute Coronary Syndrome